Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dolby Laboratories, Inc.DLB · Entity 2518 | Director · President and CEO | February 05, 2026 | February 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dolby Laboratories, Inc.
Report date February 05, 2026 · Filed February 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.62 · Expires 2035-12-15 | Direct | 145,252 |
Reported balance
After 2026-02-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-05 · Gift · Disposed 145,252 · Balance 145,252 F1: Effective February 5, 2026, the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. This transfer is exempt from Section 16(b) by virtue of Rule 16b-5. F2: This option was granted for a total of 145,252 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2025, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.62 · Expires 2035-12-15 | IndirectBy a trust | 145,252 |
Reported balance
After 2026-02-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-05 · Gift · Acquired 145,252 · Balance 145,252 F1: Effective February 5, 2026, the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. This transfer is exempt from Section 16(b) by virtue of Rule 16b-5. F2: This option was granted for a total of 145,252 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2025, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. F3: By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 |
Filing footnotes · ownership attribution and instrument terms
F1: Effective February 5, 2026, the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. This transfer is exempt from Section 16(b) by virtue of Rule 16b-5.
F2: This option was granted for a total of 145,252 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2025, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter.
F3: By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2021 Filed Dec 16, 2021 21:26 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 4,723 | $91.04 | $429,971.06 |
DisclosureSEC source: 0001209191-21-070106 · doc4.xml · nonDerivative · entry 7 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 22,690 F7 · price: This transaction was executed in multiple trades at prices ranging from $90.65 to $91.45, inclusive. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 21:26 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 29,457 | $0.00 Strike: $42.98 | $0.00 |
DisclosureSEC source: 0001209191-21-070106 · doc4.xml · derivative · entry 13 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 217,957 Underlying: Class A Common Stock · 29,457 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: This option was granted for a total of 291,598 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2014, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 21:26 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantEmployee Stock Option (Right to Buy) · Derivative | 91,047 | $0.00 Strike: $91.80 | $0.00 |
DisclosureSEC source: 0001209191-21-070106 · doc4.xml · derivative · entry 12 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,047 Underlying: Class A Common Stock · 91,047 shares Expires 2031-12-15 F11 · derivative.exercise_date: This option was granted for a total of 91,047 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2021, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 21:26 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantPerformance-Based Restricted Stock Unit · Derivative | 21,993 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070106 · doc4.xml · derivative · entry 11 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,993 Underlying: Class A Common Stock · 21,993 shares Expires not disclosed F10 · derivative.exercise_price: The vesting of this performance-based restricted stock unit ("PSU") award is dependent upon achievement of performance criteria measured during a three-year performance period beginning on December 15, 2021 and ending December 11, 2024. Each PSU represents a right to receive, upon vesting, one share of Class A common stock. The number of shares reported is at the target award amount. The reporting person may potentially earn from 0% to 200% of the target award amount based on achievement of annualized total shareholder return compared to the S&P Mid Cap 400 Index at the end of the three-year performance period. The actual PSU award earned shall vest immediately upon certification by the Company's Compensation Committee of the achievement of the performance criteria, following the end of the three-year performance period. F10 · derivative.exercise_date: The vesting of this performance-based restricted stock unit ("PSU") award is dependent upon achievement of performance criteria measured during a three-year performance period beginning on December 15, 2021 and ending December 11, 2024. Each PSU represents a right to receive, upon vesting, one share of Class A common stock. The number of shares reported is at the target award amount. The reporting person may potentially earn from 0% to 200% of the target award amount based on achievement of annualized total shareholder return compared to the S&P Mid Cap 400 Index at the end of the three-year performance period. The actual PSU award earned shall vest immediately upon certification by the Company's Compensation Committee of the achievement of the performance criteria, following the end of the three-year performance period. F10 · derivative.expiration_date: The vesting of this performance-based restricted stock unit ("PSU") award is dependent upon achievement of performance criteria measured during a three-year performance period beginning on December 15, 2021 and ending December 11, 2024. Each PSU represents a right to receive, upon vesting, one share of Class A common stock. The number of shares reported is at the target award amount. The reporting person may potentially earn from 0% to 200% of the target award amount based on achievement of annualized total shareholder return compared to the S&P Mid Cap 400 Index at the end of the three-year performance period. The actual PSU award earned shall vest immediately upon certification by the Company's Compensation Committee of the achievement of the performance criteria, following the end of the three-year performance period. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 21:26 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 8,096 | $91.17 | $738,076.70 |
DisclosureSEC source: 0001209191-21-070106 · doc4.xml · nonDerivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 27,413 F6 · price: This transaction was executed in multiple trades at prices ranging from $91.00 to $91.38, inclusive. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 21:26 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 21,361 | $90.47 | $1,932,632.20 |
DisclosureSEC source: 0001209191-21-070106 · doc4.xml · nonDerivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 35,509 F5 · price: This transaction was executed in multiple trades at prices ranging from $90.03 to $90.98, inclusive. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 21:26 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 29,457 | $42.98 | $1,266,061.86 |
DisclosureSEC source: 0001209191-21-070106 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 56,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 21:26 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantClass A Common Stock | 43,987 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070106 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,454 F3 · acquired: Award represents a total of 43,987 restricted stock units granted under the terms of the Issuer's 2020 Stock Plan. Under the terms of the restricted stock unit grant agreement, 1/4 of the total number of units shall vest on each anniversary of December 15, 2021. Each unit represents a contingent right to receive one share of the Issuer's Class A Common Stock upon vesting. F4 · balance_after: Shares held following the reported transactions include 128,454 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 21:26 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Tax withholdingClass A Common Stock | 10,882 | $90.55 | $985,365.10 |
DisclosureSEC source: 0001209191-21-070106 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,467 F1 · kind: In accordance with Rule 16b-3, shares reported as disposed of were withheld by the Issuer and not issued to the reporting person in order to cover withholding taxes incidental to the vesting of restricted stock units. F2 · balance_after: Shares held following the reported transactions include 84,467 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| November 23, 2021 Filed Nov 23, 2021 18:35 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GiftClass A Common Stock | 16,547 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-066620 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 16,348 F1 · kind: On November 23, 2021, Mr. Yeaman gifted 16,547 shares of Class A Common Stock to a Donor-Advised Fund for the purpose of making charitable donations. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 16:30 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 29,457 | $0.00 Strike: $42.98 | $0.00 |
DisclosureSEC source: 0001209191-21-066102 · doc4.xml · derivative · entry 7 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 247,414 Underlying: Class A Common Stock · 29,457 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted for a total of 291,598 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2014, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 16:30 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 13,485 | $90.81 | $1,224,563.41 |
DisclosureSEC source: 0001209191-21-066102 · doc4.xml · nonDerivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,985 F4 · price: The shares were sold in multiple transactions at prices ranging from $90.46 to $91.18, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 16:30 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 6,283 | $89.79 | $564,138.00 |
DisclosureSEC source: 0001209191-21-066102 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 46,380 F3 · price: The shares were sold in multiple transactions at prices ranging from $89.37 to $90.34, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 16:30 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 5,672 | $88.82 | $503,800.09 |
DisclosureSEC source: 0001209191-21-066102 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 52,663 F2 · price: The shares were sold in multiple transactions at prices ranging from $88.34 to $89.15 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 16:30 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 4,017 | $87.71 | $352,320.63 |
DisclosureSEC source: 0001209191-21-066102 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 58,335 F1 · price: The shares were sold in multiple transactions at prices ranging from $87.24 to $88.22, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 16:30 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 29,457 | $42.98 | $1,266,061.86 |
DisclosureSEC source: 0001209191-21-066102 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 18:57 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 14,727 | $0.00 Strike: $42.98 | $0.00 |
DisclosureSEC source: 0001209191-21-060398 · doc4.xml · derivative · entry 7 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 276,871 Underlying: Class A Common Stock · 14,727 shares Expires 2024-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted for a total of 291,598 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2014, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 18:57 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 14,730 | $0.00 Strike: $37.35 | $0.00 |
DisclosureSEC source: 0001209191-21-060398 · doc4.xml · derivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 0 Underlying: Class A Common Stock · 14,730 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted for a total of 287,265 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 16, 2013, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 18:57 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 14,727 | $87.50 | $1,288,655.21 |
DisclosureSEC source: 0001209191-21-060398 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F2 · price: The shares were sold in multiple transactions at prices ranging from $87.13 to $87.905 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 18:57 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 14,727 | $42.98 | $632,966.46 |
DisclosureSEC source: 0001209191-21-060398 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 47,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 18:57 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 14,730 | $87.56 | $1,289,695.46 |
DisclosureSEC source: 0001209191-21-060398 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F1 · price: The shares were sold in multiple transactions at prices ranging from $87.13 to $87.905, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 12, 2021 Filed Oct 13, 2021 18:57 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 14,730 | $37.35 | $550,165.50 |
DisclosureSEC source: 0001209191-21-060398 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 47,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 19:37 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 29,457 | $0.00 Strike: $37.35 | $0.00 |
DisclosureSEC source: 0001209191-21-056484 · doc4.xml · derivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 14,730 Underlying: Class A Common Stock · 29,457 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted for a total of 287,265 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 16, 2013, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 19:37 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 19,622 | $95.13 | $1,866,636.94 |
DisclosureSEC source: 0001209191-21-056484 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F2 · price: The shares were sold in multiple transactions at prices ranging from $94.87 to $95.35 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 19:37 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 9,835 | $94.35 | $927,958.80 |
DisclosureSEC source: 0001209191-21-056484 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 52,517 F1 · price: The shares were sold in multiple transactions at prices ranging from $93.87 to $94.86, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 19:37 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 29,457 | $37.35 | $1,100,218.95 |
DisclosureSEC source: 0001209191-21-056484 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 19:14 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 29,457 | $0.00 Strike: $37.35 | $0.00 |
DisclosureSEC source: 0001209191-21-050988 · doc4.xml · derivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 44,187 Underlying: Class A Common Stock · 29,457 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted for a total of 287,265 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 16, 2013, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 19:14 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 408 | $97.77 | $39,890.16 |
DisclosureSEC source: 0001209191-21-050988 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 19:14 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 9,253 | $97.18 | $899,196.36 |
DisclosureSEC source: 0001209191-21-050988 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 33,303 F2 · price: The shares were sold in multiple transactions at prices ranging from $96.77 to $97.679 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 19:14 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 19,796 | $96.03 | $1,901,093.02 |
DisclosureSEC source: 0001209191-21-050988 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 42,556 F1 · price: The shares were sold in multiple transactions at prices ranging from $95.73 to $96.62, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 19:14 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 29,457 | $37.35 | $1,100,218.95 |
DisclosureSEC source: 0001209191-21-050988 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 16:13 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 29,457 | $0.00 Strike: $37.35 | $0.00 |
DisclosureSEC source: 0001209191-21-046779 · doc4.xml · derivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 73,644 Underlying: Class A Common Stock · 29,457 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted for a total of 287,265 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 16, 2013, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 16:13 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 18,632 | $99.54 | $1,854,536.12 |
DisclosureSEC source: 0001209191-21-046779 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F2 · price: The shares were sold in multiple transactions at prices ranging from $99.36 to $99.87 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 16:13 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 10,825 | $99.09 | $1,072,630.85 |
DisclosureSEC source: 0001209191-21-046779 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 51,527 F1 · price: The shares were sold in multiple transactions at prices ranging from $98.367 to $99.34, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 16:13 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 29,457 | $37.35 | $1,100,218.95 |
DisclosureSEC source: 0001209191-21-046779 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 18:22 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 29,457 | $0.00 Strike: $37.35 | $0.00 |
DisclosureSEC source: 0001209191-21-041063 · doc4.xml · derivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 103,101 Underlying: Class A Common Stock · 29,457 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted for a total of 287,265 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 16, 2013, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 18:22 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 3,894 | $100.25 | $390,367.66 |
DisclosureSEC source: 0001209191-21-041063 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F2 · price: The shares were sold in multiple transactions at prices ranging from $99.99 to $100.62 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 18:22 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 25,563 | $99.48 | $2,542,984.23 |
DisclosureSEC source: 0001209191-21-041063 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 36,789 F1 · price: The shares were sold in multiple transactions at prices ranging from $98.98 to $99.95, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 18:22 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 29,457 | $37.35 | $1,100,218.95 |
DisclosureSEC source: 0001209191-21-041063 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2021 Filed May 12, 2021 17:09 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 900 | $95.13 | $85,619.97 |
DisclosureSEC source: 0001209191-21-032110 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F2 · price: The shares were sold in multiple transactions at prices ranging from $95.04 to $95.18 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 11, 2021 Filed May 12, 2021 17:09 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 28,557 | $94.49 | $2,698,456.59 |
DisclosureSEC source: 0001209191-21-032110 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 33,795 F1 · price: The shares were sold in multiple transactions at prices ranging from $93.9 to $94.895, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 11, 2021 Filed May 12, 2021 17:09 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 29,457 | $37.35 | $1,100,218.95 |
DisclosureSEC source: 0001209191-21-032110 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed Apr 14, 2021 17:20 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 29,457 | $0.00 Strike: $37.35 | $0.00 |
DisclosureSEC source: 0001209191-21-026680 · doc4.xml · derivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 162,015 Underlying: Class A Common Stock · 29,457 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted for a total of 287,265 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 16, 2013, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| April 13, 2021 Filed Apr 14, 2021 17:20 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 1,393 | $101.87 | $141,907.28 |
DisclosureSEC source: 0001209191-21-026680 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F2 · price: The shares were sold in multiple transactions at prices ranging from $101.79 to $101.98, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| April 13, 2021 Filed Apr 14, 2021 17:20 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 28,064 | $101.42 | $2,846,276.14 |
DisclosureSEC source: 0001209191-21-026680 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 34,288 F1 · price: The shares were sold in multiple transactions at prices ranging from $100.79 to $101.78, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| April 13, 2021 Filed Apr 14, 2021 17:20 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 29,457 | $37.35 | $1,100,218.95 |
DisclosureSEC source: 0001209191-21-026680 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 62,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed May 12, 2021 17:09 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 29,457 | $0.00 Strike: $37.35 | $0.00 |
DisclosureSEC source: 0001209191-21-032110 · doc4.xml · derivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 132,558 Underlying: Class A Common Stock · 29,457 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted for a total of 287,265 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 16, 2013, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 16:04 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 29,457 | $0.00 Strike: $37.35 | $0.00 |
DisclosureSEC source: 0001209191-21-019767 · doc4.xml · derivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 191,472 Underlying: Class A Common Stock · 29,457 shares Expires 2023-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted for a total of 287,265 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 16, 2013, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 16:04 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 19,163 | $100.10 | $1,918,199.05 |
DisclosureSEC source: 0001209191-21-019767 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 32,895 F2 · price: The shares were sold in multiple transactions at prices ranging from $99.95 to $100.32, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 16:04 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 10,294 | $99.62 | $1,025,510.93 |
DisclosureSEC source: 0001209191-21-019767 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 52,058 F1 · price: The shares were sold in multiple transactions at prices ranging from $98.95 to $99.932, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.